Kidney injuries related to ipilimumab

Hassane Izzedine; Victor Gueutin; Chems Gharbi; Christine Mateus; Caroline Robert; Emilie Routier; Marina Thomas; Alain Baumelou; Philippe Rouvier

doi:10.1007/s10637-014-0092-7

Kidney injuries related to ipilimumab

Hassane Izzedine, Victor Gueutin, Chems Gharbi, Christine Mateus, Caroline Robert, Emilie Routier, Marina Thomas, Alain Baumelou, Philippe Rouvier

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

142 Citations (Scopus)

Résumé

Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) have been investigated in metastatic melanoma and other cancers and have shown promising results. Inhibition of CTLA-4 characteristically induces well-known side effects called "immune-related adverse events" (irAEs). IrAEs mainly include colitis, dermatitis, hepatitis, endocrinopathies; uveitis, iridocyclitis, neuropathies, and inflammatory myopathy have occasionally been reported. Kidney involvement is rare. We report 2 cases of acute granulomatous interstitial nephritis and present, based on literature review, renal disorders related to Ipilimumab therapy. Autoimmune symptoms have to be carefully checked for patients treated with CTLA-4 inhibitors. In order to reduce the risk of sequelae, early recognition of irAEs and treatment initiation are crucial.

langue originale	Anglais
Pages (de - à)	769-773
Nombre de pages	5
journal	Investigational New Drugs
Volume	32
Numéro de publication	4
Les DOIs	https://doi.org/10.1007/s10637-014-0092-7
état	Publié - 1 janv. 2014

Accès au document

10.1007/s10637-014-0092-7

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{42beaf8d67604c5cb1a37329fbdb2651,

title = "Kidney injuries related to ipilimumab",

abstract = "Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) have been investigated in metastatic melanoma and other cancers and have shown promising results. Inhibition of CTLA-4 characteristically induces well-known side effects called {"}immune-related adverse events{"} (irAEs). IrAEs mainly include colitis, dermatitis, hepatitis, endocrinopathies; uveitis, iridocyclitis, neuropathies, and inflammatory myopathy have occasionally been reported. Kidney involvement is rare. We report 2 cases of acute granulomatous interstitial nephritis and present, based on literature review, renal disorders related to Ipilimumab therapy. Autoimmune symptoms have to be carefully checked for patients treated with CTLA-4 inhibitors. In order to reduce the risk of sequelae, early recognition of irAEs and treatment initiation are crucial.",

keywords = "Acute kidney injury, CTLA-4 inhibitors, Granulomatous interstitial nephritis, Melanoma",

author = "Hassane Izzedine and Victor Gueutin and Chems Gharbi and Christine Mateus and Caroline Robert and Emilie Routier and Marina Thomas and Alain Baumelou and Philippe Rouvier",

year = "2014",

month = jan,

day = "1",

doi = "10.1007/s10637-014-0092-7",

language = "English",

volume = "32",

pages = "769--773",

journal = "Investigational New Drugs",

issn = "0167-6997",

number = "4",

}

TY - JOUR

T1 - Kidney injuries related to ipilimumab

AU - Izzedine, Hassane

AU - Gueutin, Victor

AU - Gharbi, Chems

AU - Mateus, Christine

AU - Robert, Caroline

AU - Routier, Emilie

AU - Thomas, Marina

AU - Baumelou, Alain

AU - Rouvier, Philippe

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) have been investigated in metastatic melanoma and other cancers and have shown promising results. Inhibition of CTLA-4 characteristically induces well-known side effects called "immune-related adverse events" (irAEs). IrAEs mainly include colitis, dermatitis, hepatitis, endocrinopathies; uveitis, iridocyclitis, neuropathies, and inflammatory myopathy have occasionally been reported. Kidney involvement is rare. We report 2 cases of acute granulomatous interstitial nephritis and present, based on literature review, renal disorders related to Ipilimumab therapy. Autoimmune symptoms have to be carefully checked for patients treated with CTLA-4 inhibitors. In order to reduce the risk of sequelae, early recognition of irAEs and treatment initiation are crucial.

AB - Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) have been investigated in metastatic melanoma and other cancers and have shown promising results. Inhibition of CTLA-4 characteristically induces well-known side effects called "immune-related adverse events" (irAEs). IrAEs mainly include colitis, dermatitis, hepatitis, endocrinopathies; uveitis, iridocyclitis, neuropathies, and inflammatory myopathy have occasionally been reported. Kidney involvement is rare. We report 2 cases of acute granulomatous interstitial nephritis and present, based on literature review, renal disorders related to Ipilimumab therapy. Autoimmune symptoms have to be carefully checked for patients treated with CTLA-4 inhibitors. In order to reduce the risk of sequelae, early recognition of irAEs and treatment initiation are crucial.

KW - Acute kidney injury

KW - CTLA-4 inhibitors

KW - Granulomatous interstitial nephritis

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84904553412&partnerID=8YFLogxK

U2 - 10.1007/s10637-014-0092-7

DO - 10.1007/s10637-014-0092-7

M3 - Article

C2 - 24687600

AN - SCOPUS:84904553412

SN - 0167-6997

VL - 32

SP - 769

EP - 773

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -